156 results
Page 5 of 8
8-K
EX-99.1
ks4h3w8f4izv8
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
gt43u4cv688
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-99.1
1tm3bmiwlf2aj0cin
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.1
6k2f382qs4krqjv4nt2
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-10.3
gom3g364ufx9 96yhb
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
1kqu6nbecu
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.1
pzzfo h789e
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.4
vxomv64ke
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
jjy6g
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
oyoo cxwcuzanf4
20 Dec 19
Regulation FD Disclosure
8:10am
8-K
EX-1.1
qkt8ebyw49xvx x2xbpu
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
424B5
19a6ons
27 Nov 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
7bpcm9hygu3d6
20 Nov 19
Other Events
7:05am
8-K
EX-99.1
7hyl9fwnlc
8 Nov 19
CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
2:33pm
8-K
EX-99.1
5ay323c469gd
7 Nov 19
Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
EX-99.2
kofv7q
27 Sep 19
Other Events
10:15am